SCHEMBL31679341

SCHEMBL31679341

CCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](N)CS)[C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ AGTR2 P50052 5/20 0.52
▸ AGTR1 P30556 4/20 0.52
▸ NTSR1 P30989 8/20 0.50
▸ NTSR2 O95665 5/20 0.50
▸ OPRD1 P41143 2/20 0.49
▸ SORT1 Q99523 4/20 0.49
▸ F2 P00734 1/20 0.48
▸ NPY1R P25929 2/20 0.48
▸ NPY2R P49146 1/20 0.48
▸ NPY4R P50391 1/20 0.48
▸ NPY5R Q15761 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31679422 0.98 AGTR2 (0.52) AGTR2AGTR1NTSR1NTSR2OPRD1
SCHEMBL31679384 0.97 NTSR1 (0.52) AGTR2AGTR1NTSR1NTSR2SORT1
SCHEMBL31679358 0.97 AGTR2 (0.50) AGTR2AGTR1NTSR1NTSR2OPRD1
SCHEMBL31679436 0.96 NTSR1 (0.54) AGTR2AGTR1NTSR1NTSR2OPRD1
SCHEMBL31679423 0.96 AGTR2 (0.51) AGTR2AGTR1NTSR1NTSR2OPRD1
SCHEMBL31679438 0.95 AGTR2 (0.53) AGTR2AGTR1NTSR1NTSR2OPRD1
SCHEMBL31679383 0.95 AGTR2 (0.51) AGTR2AGTR1NTSR1NTSR2OPRD1
SCHEMBL31679429 0.94 OPRD1 (0.49) AGTR2AGTR1NTSR1NTSR2OPRD1
SCHEMBL31679451 0.94 AGTR2 (0.52) AGTR2AGTR1NTSR1NTSR2OPRD1
SCHEMBL31679462 0.94 AGTR2 (0.52) AGTR2AGTR1NTSR1NTSR2OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4610269-A1 UROKINASE PLASMINOGEN ACTIVATOR SURFACE RECEPTOR (UPAR) LIGANDS FOR DIAGNOSTIC OR THERAPEUTIC USE 3B Pharmaceuticals GmbH (DE) 2025-09-03 — — EP disclosed
Send feedback